Chapter 6. Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor
- Rongshi Li,
- Jeffrey A. Stafford
Published Online: 28 SEP 2009
DOI: 10.1002/9780470524961.ch6
Copyright © 2009 John Wiley & Sons, Inc.
Book Title
Kinase Inhibitor Drugs
Additional Information
How to Cite
Bhide, R. S. and Fargnoli, J. (2009) Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor, in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch6
Editor Information
Takeda San Diego, Inc., San Diego, CA 92121, USA
Publication History
- Published Online: 28 SEP 2009
- Published Print: 2 OCT 2009
ISBN Information
Print ISBN: 9780470278291
Online ISBN: 9780470524961
- Summary
- Chapter
- References
Keywords:
- brivanib alaninate discovery;
- VEGFR2 kinase domain;
- dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
Summary
This chapter contains sections titled:
Introduction
VEGFR and FGFR as Angiogenesis Targets
Discovery of Brivanib Alaninate: Preclinical Studies
Clinical Studies
Potential Liabilities of Antiangiogenic Therapy
Conclusions and Future Directions
Appendix: Formula for Calculation of Tumor Growth Inhibition
Acknowledgment
References